Answers are grounded in this paper and cite their sources.
Combined cross-sectional and longitudinal study evaluates HEV's clinical impact in cirrhosis patients, suggesting limited infection relevance.
Hepatitis E virus (HEV) is a recognized cause of acute hepatitis and a potential trigger of acute decompensation (AD) and acute-on-chronic liver failure (ACLF) in patients with cirrhosis in hyperendemic regions; however, its clinical relevance in low-endemic settings remains poorly defined. We conducted a combined cross-sectional and prospective longitudinal study to evaluate the prevalence and clinical impact of HEV infection among patients with cirrhosis in Argentina. Adult patients with mild-to-moderate cirrhosis (Child-Pugh score 6-12) of different etiologies were tested for anti-HEV IgG and IgM antibodies by ELISA and HEV RNA by RT-PCR in serum samples. Epidemiological data were collected using a structured questionnaire. In the longitudinal cohort, patients were followed for up to 24 months with serial sampling at baseline, every 6 months, and during episodes of hepatic decompensation. Anti-HEV IgG seroprevalence was 5.2% (95% CI: 2.2-11.5%), comparable to that observed in healthy blood donors, with no significant differences across cirrhosis etiologies. No patient had detectable anti-HEV IgM or HEV RNA at baseline. During follow-up, 19 patients developed hepatic decompensation, including six cases of ACLF; three patients showed anti-HEV IgG positivity, including one seroconversion, but none had evidence of acute HEV infection. These findings indicate limited HEV exposure among patients with cirrhosis in this low-endemic region and suggest that HEV infection is unlikely to represent a major trigger of AD or ACLF, although continued surveillance remains warranted.
No takes yet. Share an insight, caveat, or question.
Acosta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: